Patents by Inventor Steven R. Williams
Steven R. Williams has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8658765Abstract: This invention describes soluble, monovalent, non-natural protein molecules that can activate NK cells and certain T-cells to attack specific cellular target cells by attaching the NKG2D-binding portions of monovalent MICA or MICB protein, i.e. their ?1-?2 platform domain, to the intended target cell specifically. The ?1-?2 domain is contiguous with a heterologous ?3 domain that has been genetically modified to bind directly or indirectly to the extracellular aspect of the target cell, thereby serving as the targeting domain. The genetic modification to create a non-natural and non-terminal targeting motif within the ?3 domain can include a portion of an antibody, another protein molecule or portion thereof, a peptide, or a non-natural, modified ?3 domain of a MIC protein.Type: GrantFiled: December 30, 2010Date of Patent: February 25, 2014Assignee: AvidBiotics Corp.Inventors: David W. Martin, Jr., Steven R. Williams
-
Publication number: 20130282665Abstract: A method for archiving files includes determining when a change in an operating file is imminent, capturing the operating file immediately before the change in the operating file occurs, if the operating file has not already been captured; and capturing the operating file immediately after the change in the operating file has occurred.Type: ApplicationFiled: June 24, 2013Publication date: October 24, 2013Inventors: Warren Roach, Steven R. Williams, Troy J. Reiber, Steven C. Burdine
-
Patent number: 8473478Abstract: A method for archiving files includes determining when a change in an operating file is imminent, capturing the operating file immediately before the change in the operating file occurs, if the operating file has not already been captured; and capturing the operating file immediately after the change in the operating file has occurred.Type: GrantFiled: September 21, 2001Date of Patent: June 25, 2013Inventors: Warren Roach, Steven R. Williams, Troy J. Reiber, Steven C. Burdine
-
Patent number: 8206971Abstract: Modified forms of naturally occurring bacteriocins, such as the R-type pyocins of Pseudomonas aeruginosa, are disclosed as are methods for producing them in GRAS organisms. The bacteriocins are modified at the ends of their tail fibers in a region responsible for binding specificity and affinity to their cognate binding partners, or receptors, such as those on the surface of bacteria. Methods for the use of the modified bacteriocins, such as to bind receptors, including virulence or fitness factors, on the surfaces of bacteria, are also described.Type: GrantFiled: February 5, 2010Date of Patent: June 26, 2012Assignee: AvidBiotics CorporationInventors: Dean M. Scholl, Steven R. Williams
-
Publication number: 20110311561Abstract: This invention describes soluble, monovalent, non-natural protein molecules that can activate NK cells and certain T-cells to attack specific cellular target cells by attaching the NKG2D-binding portions of monovalent MICA or MICB protein, i.e. their ?1-?2 platform domain, to the intended target cell specifically. The ?1-?2 domain is contiguous with a heterologous ?3 domain that has been genetically modified to bind directly or indirectly to the extracellular aspect of the target cell, thereby serving as the targeting domain. The genetic modification to create a non-natural and non-terminal targeting motif within the ?3 domain can include a portion of an antibody, another protein molecule or portion thereof, a peptide, or a non-natural, modified ?3 domain of a MIC protein.Type: ApplicationFiled: July 5, 2011Publication date: December 22, 2011Applicant: AvidBiotics Corp.Inventors: David W. Martin, JR., Steven R. Williams
-
Publication number: 20110293566Abstract: This disclosure relates to the discovery and isolation of the entire cluster of genes encoding R-type high molecular weight bacteriocins that specifically kill Clostridium difficile bacteria, dangerous human pathogens. Also disclosed are methods of producing the R-type bacteriocins in innocuous producer cells that, unlike C. difficile, do not die in the presence of oxygen. Disclosed also is the specific gene of the isolated gene cluster that determines the killing spectrum of the R-type bacteriocin and the demonstration that the killing spectra of diffocins can be altered by engineering orf1374 of the diffocin genetic locus. This invention offers a potent bactericidal agent and a means to make it in order to kill selectively C. difficile bacteria in the environment of the gastrointestinal tract where they can cause great harm and even death of the infected patient or farm animal.Type: ApplicationFiled: May 27, 2011Publication date: December 1, 2011Applicant: AvidBiotics Corp.Inventors: Dean M. SCHOLL, Dana M. Gebhart, Steven R. Williams, Gregory R. Govoni, David W. Martin, JR.
-
Publication number: 20110183893Abstract: This invention describes soluble, monovalent, non-natural protein molecules that can activate NK cells and certain T-cells to attack specific cellular target cells by attaching the NKG2D-binding portions of monovalent MICA or MICB protein, i.e. their ?1-?2 platform domain, to the intended target cell specifically. The ?1-?2 domain is contiguous with a heterologous ?3 domain that has been genetically modified to bind directly or indirectly to the extracellular aspect of the target cell, thereby serving as the targeting domain. The genetic modification to create a non-natural and non-terminal targeting motif within the ?3 domain can include a portion of an antibody, another protein molecule or portion thereof, a peptide, or a non-natural, modified ?3 domain of a MIC protein.Type: ApplicationFiled: December 30, 2010Publication date: July 28, 2011Applicant: AvidBiotics CorporationInventors: David W. MARTIN, JR., Steven R. Williams
-
Publication number: 20100261258Abstract: Modified forms of naturally occurring bacteriocins, such as the R-type pyocins of Pseudomonas aeruginosa, are disclosed as are methods for producing them in GRAS organisms. The bacteriocins are modified at the ends of their tail fibers in a region responsible for binding specificity and affinity to their cognate binding partners, or receptors, such as those on the surface of bacteria. Methods for the use of the modified bacteriocins, such as to bind receptors, including virulence or fitness factors, on the surfaces of bacteria, are also described.Type: ApplicationFiled: February 5, 2010Publication date: October 14, 2010Applicant: AvidBiotics CorporationInventors: Dean M. Scholl, Steven R. Williams
-
Patent number: 7732586Abstract: Modified forms of naturally occurring bacteriocins, such as the R-type pyocins of Pseudomonas aeruginosa, are disclosed. The bacteriocins are modified at the ends of their tail fibers in a region responsible for binding specificity and affinity to their cognate binding partners, or receptors, such as those on the surface of bacteria. Methods for the use of the modified bacteriocins, such as to bind receptors, including virulence or fitness factors, on the surfaces of bacteria, are also described.Type: GrantFiled: May 14, 2007Date of Patent: June 8, 2010Assignee: AvidBiotics CorporationInventors: David W. Martin, Jr., Andrew C. Jamieson, Dean M. Scholl, Steven R. Williams
-
Patent number: 7700729Abstract: Modified forms of naturally occurring bacteriocins, such as the R-type pyocins of Pseudomonas aeruginosa, are disclosed as are methods for producing them in GRAS organisms. The bacteriocins are modified at the ends of their tail fibers in a region responsible for binding specificity and affinity to their cognate binding partners, or receptors, such as those on the surface of bacteria. Methods for the use of the modified bacteriocins, such as to bind receptors, including virulence or fitness factors, on the surfaces of bacteria, are also described.Type: GrantFiled: October 30, 2007Date of Patent: April 20, 2010Assignee: AvidBiotics CorporationInventors: Dean M. Scholl, Steven R. Williams
-
Publication number: 20080171376Abstract: Modified forms of naturally occurring bacteriocins, such as the R-type pyocins of Pseudomonas aeruginosa, are disclosed as are methods for producing them in GRAS organisms. The bacteriocins are modified at the ends of their tail fibers in a region responsible for binding specificity and affinity to their cognate binding partners, or receptors, such as those on the surface of bacteria. Methods for the use of the modified bacteriocins, such as to bind receptors, including virulence or fitness factors, on the surfaces of bacteria, are also described.Type: ApplicationFiled: October 30, 2007Publication date: July 17, 2008Applicant: AvidBiotics CorporationInventors: Dean M. SCHOLL, Steven R. WILLIAMS
-
Publication number: 20080113406Abstract: Modified forms of naturally occurring bacteriocins, such as the R-type pyocins of Pseudomonas aeruginosa, are disclosed. The bacteriocins are modified at the ends of their tail fibers in a region responsible for binding specificity and affinity to their cognate binding partners, or receptors, such as those on the surface of bacteria. Methods for the use of the modified bacteriocins, such as to bind receptors, including virulence or fitness factors, on the surfaces of bacteria, are also described.Type: ApplicationFiled: May 14, 2007Publication date: May 15, 2008Applicant: AvidBiotics CorporationInventors: David W. Martin, Andrew C. Jamieson, Dean M. Scholl, Steven R. Williams
-
Publication number: 20030049616Abstract: The invention provides oligonucleotide tag compositions and methods for synthesizing repertoires of error-free oligonucleotide tags that may be used for labeling and sorting polynucleotides, such as cDNAs, restriction fragments, and the like. In accordance with the method of the invention, oligonucleotide tag precursors are provided in an amplicon, wherein the tag precursors each consists of one or more oligonucleotide “words” selected from the same minimally cross-hybridizing set of words. The oligonucleotide tag precursors are elongated by repeated cycles of cleavage, ligation of one or more words, and amplification. Cycles continue until the oligonucleotide tags of the repertoire have a desired length or complexity.Type: ApplicationFiled: January 8, 2001Publication date: March 13, 2003Inventors: Sydney Brenner, Steven R. Williams
-
Patent number: 6514752Abstract: Homologous recombination is employed to inactivate genes, particularly genes associated with MHC antigens. Particularly, the &bgr;2-microglobulin gene is inactivated for reducing or eliminating the expression of functional Class I MHC antigens. The resulting cells may be used as universal donor cells. In addition, embryonic stem cells may be modified by homologous recombination for use in producing chimeric or transgenic mammalian hosts, which may be used as source of universal donor organs, or as models for drug and transplantation therapies. Methods for homologous recombination in non-transformed mammalian somatic cells are also described.Type: GrantFiled: May 18, 1995Date of Patent: February 4, 2003Assignee: Cell Genesys, Inc.Inventors: Raju Kucherlapati, Beverly H. Koller, Oliver Smithies, Robert B. Dubridge, Gary Greenburg, Daniel J. Capon, Steven R. Williams, Mariona Lourdes Arbones De Rafael
-
Publication number: 20020065837Abstract: A method for archiving files includes determining when a change in an operating file is imminent, capturing the operating file immediately before the change in the operating file occurs, if the operating file has not already been captured; and capturing the operating file immediately after the change in the operating file has occurred.Type: ApplicationFiled: September 21, 2001Publication date: May 30, 2002Inventors: Warren Roach, Steven R. Williams, Troy J. Reiber, Steven C. Burdine
-
Patent number: 6139835Abstract: Homologous recombination is employed to inactivate genes, particularly genes associated with MHC antigens. Particularly, the .beta..sub.2- microglobulin gene is inactivated for reducing or eliminating the expression of functional Class I MHC antigens. The resulting cells may be used as allogeneic donor cells. Methods for homologous recombination in non-transformed mammalian somatic cells are also described.Type: GrantFiled: May 18, 1995Date of Patent: October 31, 2000Assignee: Cell Genesys, Inc.Inventors: Raju Kucherlapati, Beverly H. Koller, Oliver Smithies, Robert B. Dubridge, Gary Greenburg, Daniel J. Capon, Steven R. Williams, Mariona Lourdes Arbones De Rafael
-
Patent number: 5574205Abstract: Homologous recombination is employed to inactivate genes, particularly genes associated with MHC antigens. Particularly, each of the .beta..sub.2- microglobulin gene and the IFN-.gamma.R gene is inactivated for reducing or eliminating the expression of functional MHC antigens. The resulting cells may be used as universal donor cells. In addition, embryonic stem cells may be modified by homologous recombination for use in producing chimeric or transgenic mammalian hosts, which may be used as source of universal donor organs, or as models for drug and transplantation therapies. Methods for homologous recombination in non-transformed mammalian somatic cells are also described.Type: GrantFiled: December 30, 1993Date of Patent: November 12, 1996Assignee: Cell GenesysInventors: Raju Kucherlapati, Beverly H. Koller, Oliver Smithies, Robert B. Dubridge, Gary Greenburg, Daniel J. Capon, Steven R. Williams, Mariona L. A. De Rafael
-
Patent number: 5134701Abstract: The test apparatus for monitoring the operation of a processor that has multiple instruction fetch capability monitors the instruction memory to record the sequence of program instructions that are retrieved by the processor from program memory. The test apparatus determines when a jump operation is executed and determines the target of the jump oepration by inserting a break point instruction in place of one of the two program instructions that is retrieved by the processor from program memory. This instruction substitution is accomplished by an instruction jamming circuit that forces the break point instruction onto the processor data bus as part of the program instruction fetch cycle in lieu of one of the instruction retrieved as part of the execution of the jump instruction.Type: GrantFiled: February 10, 1989Date of Patent: July 28, 1992Assignee: Hewlett-Packard Co.Inventors: David C. Mueller, Steven R. Williams, Nabil M. Abu-Jbara